News Sentiment

TLX sentiment intelligence

Telix Pharmaceuticals Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 66 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 11.14 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

85/100 classification confidence.

Company focus 58

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-6.1% over one week, +16.5% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Telix opens radiopharmaceutical facility in Australia for cancer treatment

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 85/100 classification
One-week reaction -6.1% Price reacting lower
Trend fit Trend active 16.5% over four weeks
Fair value -11.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 30
Neutral 32
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 58
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 8
Stock Titan 7
Simply Wall Street 5
Kalkine 4
PR Newswire 3
The National Law Review 3
Ad-hoc-news.de 2
TradingView 2

Event Lens

What the news is about

Classified themes
Market update 45
Earnings 11
Regulatory and legal 5
Guidance 2
Macro sensitivity 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 66
PR Newswire Asia Direct company coverage

First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer

Telix Pharmaceuticals Limited and St Vincent's Hospital have dosed the first patients in the OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The Phase 2 study evaluates TLX597-Tx, a next-generation PSMA-targeting radioligand therapy, in combination with

Tone
Positive 92/100
Event
Market update
Published
15 Jul 2026 20:44
Source
PR Newswire Asia
Stock Titan Direct company coverage

Telix Tests Targeted Therapy Earlier in Metastatic Prostate Cancer

Telix Pharmaceuticals, in collaboration with St Vincent’s Hospital Sydney, has dosed the first patients in its Phase 2 OPTIMAL-e trial for metastatic hormone-sensitive prostate cancer (mHSPC). The trial evaluates TLX597-Tx, a PSMA-targeting radioligand therapy, in combination wit

Tone
Positive 67/100
Event
Market update
Published
15 Jul 2026 20:44
Source
Stock Titan
Kavout | AI Direct company coverage

What's Driving Telix's Latest FDA Resubmission for Pixclara®

Telix Pharmaceuticals has resubmitted its New Drug Application (NDA) for Pixclara® (TLX101-Px), a PET imaging agent for brain cancer, to the U.S. FDA, addressing previous data requests. The drug holds Orphan Drug and Fast Track designations, indicating an urgent medical need and

Tone
Positive 70/100
Event
Market update
Published
11 Jul 2026 10:42
Source
Kavout | AI
The National Law Review Direct company coverage

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Telix Pharma

Levi & Korsinsky, LLP has announced a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements about the progress of its prostate cancer therapeutic candidates and the qua

Tone
Negative 8/100
Event
Regulatory and legal
Published
11 Jul 2026 10:39
Source
The National Law Review
Kalkine Direct company coverage

Is Telix Pharmaceuticals (ASX:TLX) Trading Near its 52-Week High or Low?

Telix Pharmaceuticals (ASX:TLX) shares increased by 2.17% to AUD 16.940, closing at its intraday high during the latest trading session. The company's market capitalization reached approximately AUD 5.62 billion, though trading volume was below average. Despite the gain, the stoc

Tone
Positive 64/100
Event
Market update
Published
09 Jul 2026 13:48
Source
Kalkine
Ad-hoc-news.de Direct company coverage

Telix Pharmaceuticals strengthens radiopharmaceutical pipeline as oncology demand grows

Telix Pharmaceuticals Ltd is expanding its portfolio of targeted radiopharmaceuticals to meet the increasing global demand for oncology treatment. The Australian company focuses on precision cancer imaging and therapy, particularly with radiolabeled molecules, and has a diversifi

Tone
Positive 74/100
Event
Macro sensitivity
Published
09 Jul 2026 11:48
Source
Ad-hoc-news.de
TradingView Direct company coverage

Telix Pharmaceuticals Limited Actuals & Estimates (ASX:TLX)

This article provides an overview of Telix Pharmaceuticals Limited (ASX:TLX) financial actuals and estimates. It covers current stock price, historical performance, analyst forecasts ranging from 17.94 AUD to 31.78 AUD, and key financial metrics including market capitalization, e

Tone
Positive 61/100
Event
Analyst action
Published
09 Jul 2026 09:40
Source
TradingView
AD HOC NEWS Direct company coverage

Telix Pharmaceuticals Ltd updates investors as radiopharmaceutical pipeline advances

Telix Pharmaceuticals Ltd is updating investors on its radiopharmaceutical pipeline and global expansion strategy, focusing on targeted cancer imaging and therapy. The company aims to provide more accurate diagnosis and treatment for solid tumors through its precision oncology pr

Tone
Positive 70/100
Event
Market update
Published
08 Jul 2026 17:52
Source
AD HOC NEWS
DirectorsTalk Interviews Direct company coverage

Telix Pharmaceuticals Limited (TLX): Investor Outlook Unveils 75% Upside Potential

Telix Pharmaceuticals (TLX), an Australian biopharmaceutical company focusing on radiopharmaceuticals, is drawing significant investor interest with its promising growth and substantial upside potential. Despite current unprofitability, analysts maintain a strong buy rating, with

Tone
Positive 73/100
Event
Guidance
Published
06 Jul 2026 10:25
Source
DirectorsTalk Interviews
AD HOC NEWS Direct company coverage

Telix Pharmaceuticals builds on radiopharmaceutical pipeline as investors watch oncology growth

Telix Pharmaceuticals, an Australian radiopharmaceutical company, is expanding its oncology pipeline by developing targeted radiation therapies for cancer diagnosis and treatment. The company focuses on integrated imaging and therapy (theranostics) for various cancers and employs

Tone
Positive 71/100
Event
Market update
Published
05 Jul 2026 17:39
Source
AD HOC NEWS
Simply Wall Street Direct company coverage

Telix Pharmaceuticals (ASX:TLX) Clears FDA Trial Step, Does It Look Fairly Valued?

Telix Pharmaceuticals (ASX:TLX) recently confirmed with the FDA that safety data from its ProstACT Global Phase 3 trial supports advancing TLX591-Tx. After a significant stock appreciation, analysts estimate the company is still undervalued, though it faces risks like an SEC subp

Tone
Positive 67/100
Event
Market update
Published
03 Jul 2026 20:09
Source
Simply Wall Street
Stock Titan Direct company coverage

FDA backs Telix (NASDAQ: TLX) ProstACT Global Phase 3 trial design

Telix Pharmaceuticals has announced FDA alignment regarding its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that Part 1 safety data are sufficient to advance to Part 2 in the U.S. and agreed with the clinical p

Tone
Positive 71/100
Event
Market update
Published
03 Jul 2026 09:42
Source
Stock Titan
Moomoo Direct company coverage

Telix Pharmaceuticals Ltd (TLX.AU) Short interest going down consistently!

The article highlights that Telix Pharmaceuticals Ltd (TLX.AU) is experiencing a consistent decrease in short interest. This information was posted by a user named 152291402 on the moomoo Community platform. The post suggests a positive sentiment regarding the stock, as reduced s

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 07:41
Source
Moomoo
The National Law Review Direct company coverage

Did You Lose Money on Telix Pharmaceuticals Ltd. (TLX)? Levi & Korsinsky Urges Investors to Act Before January 9, 2026

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) on behalf of investors who purchased its securities. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements about the progress of its pr

Tone
Negative 18/100
Event
Regulatory and legal
Published
03 Jul 2026 01:09
Source
The National Law Review
www.marketscreener.com Direct company coverage

Telix Pharmaceuticals : FDA Alignment to Advance ProstACT Global Phase 3 Trial

Telix Pharmaceuticals announced alignment with the U.S. FDA to advance the ProstACT Global Phase 3 trial for its therapeutic candidate TLX591-Tx in metastatic castration-resistant prostate cancer. The FDA confirmed that initial safety data is sufficient to allow progression into

Tone
Positive 70/100
Event
Market update
Published
02 Jul 2026 20:09
Source
www.marketscreener.com
Sahm Direct company coverage

FDA Alignment to Advance ProstACT Global Phase 3 Trial

Telix Pharmaceuticals announced a successful Type B meeting with the FDA, securing alignment to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer into the U.S. The FDA approved the safety data from Part 1 and agre

Tone
Positive 71/100
Event
Market update
Published
02 Jul 2026 09:11
Source
Sahm
Moomoo Direct company coverage

Telix Pharmaceuticals Says FDA Clears Path to Advance Phase 3 Study of Prostate Cancer Drug Candidate

Telix Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for TLX250-CDx. This clearance allows Telix to proceed with a global Phase 3 study of the prostate cancer imaging agent. The study aims to e

Tone
Positive 71/100
Event
Regulatory and legal
Published
02 Jul 2026 08:10
Source
Moomoo
grafa.com Direct company coverage

Telix Pharmaceuticals aligns with FDA on Phase 3 trial

Telix Pharmaceuticals has aligned with the US FDA on its global Phase 3 clinical trial protocol for prostate cancer, following a successful 36-patient safety study. This agreement allows the company to expand recruitment into the US market, with its shares experiencing upward tra

Tone
Positive 93/100
Event
Market update
Published
02 Jul 2026 04:09
Source
grafa.com
Stock Titan Direct company coverage

Telix clears FDA protocol review for prostate cancer trial expansion

Telix Pharmaceuticals announced that the U.S. FDA has agreed for its ProstACT Global Phase 3 trial to advance to Part 2 in the United States, based on sufficient safety data from Part 1. The FDA also aligned with Telix on the clinical protocol, statistical analysis plan, and safe

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 04:09
Source
Stock Titan
Sharecafe Direct company coverage

Telix Pharmaceuticals Secures FDA Alignment for Key Prostate Cancer Trial in U.S.

Telix Pharmaceuticals has secured alignment with the FDA to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer in the U.S. The FDA reviewed safety and dosimetry data from Part 1 and the Part 2 protocol design, conf

Tone
Positive 72/100
Event
Market update
Published
02 Jul 2026 00:09
Source
Sharecafe
Simply Wall Street Direct company coverage

Is Telix (ASX:TLX) Using Vertical Integration To Quietly Redefine Its Radiopharmaceutical Moat?

Telix Pharmaceuticals is leveraging vertical integration and strategic deal-making in manufacturing and distribution to strengthen its position in the radiopharmaceutical market for precision oncology. While the company projects significant revenue and earnings growth by 2029, in

Tone
Positive 67/100
Event
Earnings
Published
01 Jul 2026 11:40
Source
Simply Wall Street
The National Law Review Direct company coverage

Class Action Lawsuit Filed Against Telix Pharmaceuticals Ltd. (TLX) - Recover Losses - Contact Levi & Korsinsky Before January 9, 2026

A class action lawsuit has been filed against Telix Pharmaceuticals Ltd. (TLX) on behalf of investors who purchased securities between February 21, 2025, and August 28, 2025. The lawsuit alleges that Telix Pharmaceuticals made false and misleading statements regarding the progres

Tone
Negative 13/100
Event
Regulatory and legal
Published
01 Jul 2026 09:09
Source
The National Law Review
Simply Wall Street Direct company coverage

Telix Pharmaceuticals Stock Leads 3 Australian Growth Picks With High Insider Ownership

This article highlights three Australian growth stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). Telix Pharmaceuticals is noted for its commercial-stage biopharmaceutical operations and canc

Tone
Positive 70/100
Event
Market update
Published
30 Jun 2026 05:10
Source
Simply Wall Street
Market Index Direct company coverage

ChartWatch ASX Scans: Pro Medicus, Life360, Telix Pharmaceuticals, Zip Co, Global X Cybersecurity ETF, Lindian Resources

This article provides daily ASX scans based on Carl Capolingua's trend following technical analysis methodology, highlighting interesting uptrends and downtrends. It lists companies like Life360, Pro Medicus, and Telix Pharmaceuticals in uptrends, and Autosports and Bellevue Gold

Tone
Positive 64/100
Event
Market update
Published
30 Jun 2026 02:10
Source
Market Index
Simply Wall Street Direct company coverage

Fast Growing Australian Stocks With High Insider Ownership Worth A Closer Look

This article highlights three fast-growing Australian stocks with high insider ownership: Telix Pharmaceuticals (ASX:TLX), Lindian Resources (ASX:LIN), and GemLife Communities Group (ASX:GLF). It discusses their business models, market performance, growth prospects, and associate

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 01:41
Source
Simply Wall Street